Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma

The effectivenes of cancer vaccines in inducing CD8+Tcell responses remains a challenge, resulting in a need for testing more potent adjuvants. Our objective was to determine the safety and immunogenicity of vaccination against melanoma-related antigens employing MART-1, gp100, and tysosinase paptid...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tarhini, Ahmad A, Leng, Siyang, Moschos, Stergios J, Yin, Yan, Sander, Cindy, Lin, Yan, Gooding, William E, Kirkwood, John M
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483091/
https://ncbi.nlm.nih.gov/pubmed/22495394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e31825481fe
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky